Illumina, Inc. $ILMN Stock Acquired by TD Waterhouse Canada Inc.

Posted by Brenda Bartman on Oct 18th, 2026

TD Waterhouse Canada Inc. boosted its holdings in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 599.2% in the third quarter, HoldingsChannel reports. The firm owned 127,357 shares of the life sciences company’s stock after purchasing an additional 109,142 shares during the period. TD Waterhouse Canada Inc.’s holdings in Illumina were worth $33,892,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Baker Tilly Wealth Management LLC boosted its holdings in shares of Illumina by 3.3% during the 3rd quarter. Baker Tilly Wealth Management LLC now owns 1,297 shares of the life sciences company’s stock worth $355,000 after buying an additional 42 shares in the last quarter. Elevation Wealth Partners LLC grew its position in shares of Illumina by 19.7% during the 3rd quarter. Elevation Wealth Partners LLC now owns 292 shares of the life sciences company’s stock worth $80,000 after buying an additional 48 shares during the period. Valeo Financial Advisors LLC grew its position in shares of Illumina by 1.5% during the 3rd quarter. Valeo Financial Advisors LLC now owns 4,031 shares of the life sciences company’s stock worth $1,103,000 after buying an additional 61 shares during the period. Meeder Advisory Services Inc. increased its stake in shares of Illumina by 3.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after acquiring an additional 85 shares in the last quarter. Finally, Gabelli Funds LLC increased its stake in shares of Illumina by 2.0% in the 1st quarter. Gabelli Funds LLC now owns 5,000 shares of the life sciences company’s stock valued at $616,000 after acquiring an additional 100 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Illumina

In other Illumina news, Director Keith Meister sold 457,858 shares of Illumina stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the transaction, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders sold 2,061,850 shares of company stock worth $436,479,102. 2.90% of the stock is currently owned by insiders.

Illumina Trading Down 2.0%

Shares of Illumina stock opened at $262.54 on Friday. The stock has a market capitalization of $39.64 billion, a PE ratio of 48.98, a price-to-earnings-growth ratio of 3.72 and a beta of 1.41. Illumina, Inc. has a 52 week low of $94.00 and a 52 week high of $309.35. The stock has a 50 day moving average price of $234.53 and a two-hundred day moving average price of $186.01. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN – Get Free Report) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the previous year, the firm posted $1.19 earnings per share. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ILMN. TD Cowen boosted their target price on shares of Illumina from $210.00 to $270.00 and gave the company a “hold” rating in a research report on Tuesday. Royal Bank Of Canada raised their price target on shares of Illumina from $230.00 to $310.00 and gave the stock an “outperform” rating in a report on Monday, October 5th. Argus raised their price target on shares of Illumina from $180.00 to $235.00 and gave the stock a “buy” rating in a report on Thursday, September 3rd. Deutsche Bank Aktiengesellschaft downgraded shares of Illumina to a “hold” rating in a research note on Wednesday, August 5th. Finally, Sanford C. Bernstein reiterated a “market perform” rating and set a $215.00 price objective on shares of Illumina in a report on Friday, July 31st. Ten investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $225.94.

View Our Latest Stock Analysis on Illumina

Illumina Company Profile

(Free Report)

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.